Immunotherapies are becoming increasingly important for improved treatment of a variety of cancer types. However, the development of these novel therapies has outstripped our understanding of underlying mechanisms and how best to apply them. It is therefore crucial that we use tools such as MRI, and other molecular imaging techniques, to evaluate immunotherapies in both the clinic and in preclinical studies, and develop new probes and biomarkers to increase their efficacy. This talk will explore the work being done by a number of labs utilizing MRI, including the development of novel probes and biomarkers (both prognostic and diagnostic).
This abstract and the presentation materials are available to members only; a login is required.